Clinical trials: Metronidazole
Clostridium Difficile Infection
Bezlotoxumab (MK-6072) Versus Placebo in Children With Clostridium Difficile Infection (CDI) (MK-6072-001)
The primary objectives of this study are to evaluate the pharmacokinetics (PK), safety, and tolerability of bezlotoxumab (MK-6072) in children aged 1 to <18 years of age with a confirmed diagnosis of Clostridium difficile…
- Trial name
- MODIFY III (NCT03182907)
- Testing
- Bezlotoxumab, Antibacterial drug treatment (ABD)
- Where
- 75 sites in United States, Argentina and 15 more
- Volunteers
- 148 people
- Sponsor
- Merck Sharp & Dohme LLC
Intra-abdominal Infections
A Phase 3 Study Of Intravenous Metronidazole For Intrabdominal Infection
The purpose of this study is to evaluate the clinical efficacy and safety in Japanese adult subjects with Intra-abdominal/Pelvic infections receiving Metronidazole IV 1,500-2,000 mg/day in combination with ceftriaxone sodium.
- Trial name
- NCT01473836
- Testing
- Metronidazole, Ceftriaxone sodium
- Where
- 15 sites in Japan
- Volunteers
- 38 people
- Sponsor
- Pfizer
Gram-negative Bacterial Infections
Study of 2 Medicines (Aztreonam and Avibactam) Compared to Best Available Therapy for Serious Gram-negative Infections
The purpose of this study is to evaluate how Aztreonam (ATM) and Avibactam (AVI) are processed in pediatric participants. This study also aims to understand participant safety and effects in pediatric participants.
- Trial name
- NCT05639647
- Testing
- ATM-AVI, BAT
- Where
- 22 sites in United States, China and 6 more
- Volunteers
- 48 people
- Sponsor
- Pfizer
Subacute Stroke
MiGo Tracker Remote Monitoring of Home Exercise After Stroke
This project will determine the safety and effectiveness of a MiGo Tracker RTM program in a randomized controlled trial with individuals with subacute stroke (N=50).
- Trial name
- NCT06752707
- Testing
- MiGo Tracker, Conventional home exercise program
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Flint Rehabilitation Devices, LLC
Vaginal Candidiasis, Bacterial Vaginosis
Observational Program Neo-Penotran® Forte
Vaginitis is the most common gynecologic diagnosis in the primary care setting. In approximately 90 percent of affected women, this condition occurs secondary to bacterial vaginosis, vulvovaginal candidiasis, trichomoniasis or…
- Conditions
- Vaginal Candidiasis, Bacterial Vaginosis, Trichomonal Vaginitis
- Trial name
- NCT01335373
- Testing
- Metronidazole/Miconazole (Neo-Penotran Forte, BAY86-5276)
- Where
- Kazakhstan
- Volunteers
- 13,024 people
- Sponsor
- Bayer
Infection, Intra-abdominal
Dragon Study (the Safety and Efficacy for Treatment of Patients With Complicated Intra Abdominal Infections)
The purpose of this study is to assess the safety and efficacy of intravenous administration Moxifloxacin (BAY 12-8039) compared to intravenous ceftriaxone and metronidazole for the treatment of patients with complicated intra…
- Trial name
- DRAGON (NCT00769171)
- Testing
- Avelox (Moxifloxacin, BAY12-8039), Ceftriaxone + Metronidazole
- Where
- 25 sites in China, Hong Kong and 4 more
- Volunteers
- 364 people
- Sponsor
- Bayer
BACTERIAL VAGINOSIS
Efficacy and Safety Study of Rifaximin Vaginal Tablets in Bacterial Vaginosis
THE STUDY HAS BEEN DESIGNED TO COMPARE THE EFFICACY OF TWO DOSES (25 MG AND 100 MG) OF RIFAXIMIN VAGINAL TABLETS VERSUS PLACEBO IN SUBJECTS WITH BACTERIAL VAGINOSIS
- Trial name
- VARIANT (NCT02376972)
- Testing
- RIFAXIMIN VAGINAL TABLET 25 MG, RIFAXIMIN VAGINAL TABLET 100 MG, METROGEL VAGINAL
- Where
- United States
- Volunteers
- 392 people
- Sponsor
- Alfasigma S.p.A.
Malodorous Infected Cutaneous Ulcer
An Open, Uncontrolled Study of GK567 in the Deodorization of Malodorous Fungating Neoplastic Tumours
This clinical trial objective is to investigate the safety and efficacy of GK567 to alleviate malodour of foul smelling, anaerobically infected fungating neoplastic tumours, over 14 days of treatment.
- Trial name
- GK567 (NCT01541930)
- Testing
- GK567
- Where
- 2 sites in Japan
- Volunteers
- 21 people
- Sponsor
- Galderma R&D
Healthcare Fraud Schemes, Kickback Networks
Healthcare Integrity & Anti-Fraud Enforcement
The PHX-AFK-US Protocol is a coalition-backed regulatory scaffold designed to restore healthcare integrity across U.S. facilities.
- Conditions
- Healthcare Fraud Schemes, Kickback Networks, Supply Chain Vulnerabilities, Governance Failures
- Trial name
- PHX-AFK-US (NCT07217730)
- Testing
- Validator-Governed Reform & Regulatory Escalation Protocol, Coalition-Grade Validator Dashboard Module (CVDM-1), Coalition-Flagged Pharmaceutical Audit Trigger (CFPAT-1)
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Truway Health, Inc.
Clostridium Difficile Infection (CDI)
Study of Metronidazole Delayed-Release Capsules in Comparison With Immediate-Release Tablets (Flagyl) for Safety and Pharmacokinetics
Clostridium difficile Infection (CDI) also referred to as Clostridium difficile associated diarrhea (CDAD) is an infectious disease that is commonly associated with taking broad-spectrum antimicrobials and certain cancer…
- Trial name
- NCT07251127
- Testing
- Delayed-release metronidazole, Immediate-release metronidazole
- Where
- India
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Gateway Pharmaceutical LLC
Childhood Asthma
Asthma Control Study
The "Digital Health Tool for Parental Management of Childhood Asthma -- Impact on Asthma Control Test Scores" Study is a 16 week, prospective, intent-to-treat, 2-arm randomized controlled trial that aims to evaluate the impact of…
- Trial name
- NCT03304067
- Testing
- Tueo Program
- Where
- United States
- Volunteers
- 262 people
- Sponsor
- Evidation Health
Clostridium Difficile Associated Diarrhea
A Safety, Tolerability and Pharmacokinetic Study of Two Formulations of Metronidazole Versus Immediate Release Metronidazole in Patient With C. Difficile Colitis
Clostridium difficile bacteria can be a cause of significant diarrheal disease, particularly in people who have taken potent antibiotics. When C.
- Trial name
- NCT01559545
- Testing
- Metronidazole, Metronidazole-DRF1, Metronidazole-DRF2
- Where
- 12 sites in India
- Volunteers
- 60 people
- Sponsor
- Dr. Reddy's Laboratories Limited
Bacterial Vaginosis
Study Evaluating the Equivalence of GDC-229 and Metronidazole Vaginal Gel 0.75% in the Treatment of Bacterial Vaginosis
This research study is being done to compare the safety and efficacy of GDC-229 (test drug) against the currently marketed reference drug (metronidazole 0.75% vaginal gel) and to establish that these two drugs work better than…
- Trial name
- NCT03091777
- Testing
- GDC-229, Metronidazole Vaginal Gel 0.75%
- Where
- United States
- Volunteers
- 871 people
- Sponsor
- Balmoral Medical company
Intra-abdominal Infection
A Study to Evaluate the Safety and Effectiveness of Ertapenem Versus Ceftriaxone/Metronidazole in the Treatment of Intra-abdominal Infections in Adults (0826-802)
A multicenter study to evaluate the effectiveness of ertapenem compared to ceftriaxone/metronidazole in treating certain abdominal infections that require surgery in adult patients.
- Trial name
- NCT00481702
- Testing
- Comparator: ceftriaxone sodium / Duration of Treatment: 8 Weeks, MK0826, /Duration of Treatment : 8 Weeks, Comparator: metronidazole / Duration of Treatment: 8 Weeks
- Volunteers
- 300 people
- Sponsor
- Merck Sharp & Dohme LLC
Obstructive Sleep Apnea
Safety and Effectiveness of Slow Wave Device for the Treatment of Obstructive Sleep Apnea
This is a safety and efficacy trial for a Slow Wave, Inc. UASD oral appliance for the treatment of Obstructive Sleep Apnea. This trial will recruit 60-80 participants through our IRB partner.
- Trial name
- NCT06519149
- Testing
- Slow Wave UASD
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Slow Wave, Inc.
Erythematotelangiectatic Rosacea, Papulopustular Rosacea
Study to Evaluate the Efficacy and Safety of PAC-14028 Cream in Rosacea Patients
The objective of this study is to determine the efficacy and safety of PAC-14028 1% cream of Amorepacific Corporation in patients with erythema-telangiectatic or papulopustular rosacea
- Trial name
- NCT02052999
- Testing
- PAC-14028 cream 1%, Vehicle, Rozex gel 0.75%
- Where
- South Korea
- Volunteers
- 80 people
- Sponsor
- Amorepacific Corporation
Functional Gastrointestinal Disorders (FGIDs), Weight Loss
Effects of Multi-strain Bacillus Spore Probiotics on Growth, Digestive Function, and Gut Microbiota in Cesarean-Delivered Neonates
Infants born by cesarean section commonly show early weight loss and slower recovery of birth weight, together with characteristic patterns of gut microbiota dysbiosis marked by reduced Bifidobacterium and Bacteroides and…
- Trial name
- NCT07320287
- Testing
- RO water, LiveSpo PREG-MOM, LiveSpo CONSY
- Where
- Vietnam
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Anabio R&D
Community Acquired Bacterial Pneumonia, Complicated Intra-Abdominal Infection
Study Evaluating Tigecycline Versus Ceftriaxone In Complicated Intra-Abdominal Infections & Community Acquired Pneumonia
The main purpose of this study is to compare the safety of tigecycline versus a ceftriaxone regimen in pediatric subjects (aged 8 to 17 years) with complicated intra-abdominal infections (cIAI) and community acquired pneumonia…
- Trial name
- NCT01602874
- Testing
- Tigecycline, cIAI: Ceftriaxone with metronidazole, plus if applicable aminoglycoside, CAP: Ceftriaxone, plus if applicable oral clarithromycin
- Sponsor
- Pfizer
Community Acquired Bacterial Pneumonia, Complicated Intra-Abdominal Infection
Study Evaluating Tigecycline Versus Ceftriaxone In Complicated Intra-Abdominal Infections & Community Acquired Pneumonia
The main purpose of this study is to compare the safety of tigecycline versus a ceftriaxone regimen in pediatric subjects (aged 8 to 17 years) with complicated intra-abdominal infections (cIAI) and community acquired pneumonia…
- Trial name
- NCT00914888
- Testing
- Tigecycline, cIAI: Ceftriaxone with metronidazole, plus if applicable aminoglycoside, CAP: Ceftriaxone, plus if applicable oral clarithromycin
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Sexual Active Women, Vaginal Discharge
Efficacy and Safety of the Association of Clotrimazole and Metronidazole in the Treatment of Vaginal Discharge From Different Etiologies.
The purpose of this study is to determine the efficacy and safety of the association clotrimazole 200mg and metronidazole 0,75%(Clopistatin 5DT®) and whether it is superior when compared with metronidazole 100mg/g (gynecologic…
- Trial name
- Frauen (NCT02713139)
- Testing
- Clotrimazole + Metronidazole, Metronidazole, Clotrimazole
- Sponsor
- Ache Laboratorios Farmaceuticos S.A.